I-MAB (IMAB) Price & Analysis

Q: What was I-MAB’s price range in the past 12 months?

I-MAB lowest stock price was $0.59 and its highest was $5.90 in the past 12 months.

Q: What is I-MAB’s market cap?

I-MAB’s market cap is $346.07M.

Q: When is I-MAB’s upcoming earnings report date?

I-MAB’s upcoming earnings report date is Nov 13, 2025 which is in 34 days.

Q: How were I-MAB’s earnings last quarter?

I-MAB released its earnings results on Aug 20, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.054 by $0.024.

Q: Is I-MAB overvalued?

According to Wall Street analysts I-MAB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does I-MAB pay dividends?

I-MAB does not currently pay dividends.

Q: What is I-MAB’s EPS estimate?

I-MAB’s EPS estimate is -0.04.

Q: How many shares outstanding does I-MAB have?

I-MAB has 81,660,350 shares outstanding.

Q: What happened to I-MAB’s price movement after its last earnings report?

I-MAB reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.054. Following the earnings report the stock price went up 7.363%.

Q: Which hedge fund is a major shareholder of I-MAB?

Currently, no hedge funds are holding shares in IMAB

Compare

409 Followers

IMAB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.60 - $5.90

Previous CloseN/A

Volume876.01K

Average Volume (3M)1.55M

Market Cap

$346.07M

Enterprise Value$35.53M

Total Cash (Recent Filing)$184.39M

Total Debt (Recent Filing)$3.78M

Price to Earnings (P/E)―

Beta1.78

Next Earnings

Nov 13, 2025

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding81,660,350

10 Day Avg. Volume1,537,428

30 Day Avg. Volume1,547,660

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.34

Price to Sales (P/S)0.00

P/FCF Ratio-1.31

Enterprise Value/Market Cap0.10

Enterprise Value/Revenue8.89

Enterprise Value/Gross Profit8.89

Enterprise Value/Ebitda-0.12

Forecast

1Y Price Target

$7.40

Price Target Upside45.96% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentGivastomig’s upcoming Ph 1b dose expansion update is a significant value-inflection point for the stock, and optimism surrounds the expected clinical data.

Financial PositionThe August 2025 financing extends cash runway into the fourth quarter of 2028, allowing I-Mab to carry givastomig through a randomized Phase 2 trial.

Pipeline ExpansionI-Mab announced it will be expanding clinical development of givastomig (giva) to include other CLDN18.2 positive tumors including PDAC and biliary tract cancer (BTC).

Bears Say

Market PerceptionI-Mab shares fell ~20% following a New York Times article, which is seen as an unwarranted mispricing due to the mischaracterization of I-Mab as a Chinese drugmaker.

Regulatory ConcernsThe NY Times article focuses on China drug import restrictions, which does not apply to I-Mab. I-Mab is a U.S.-based biotech company with all clinical operations and personnel based in the U.S.

I-MAB News

I-Mab initiated with an Outperform at Leerink

Leerink analyst Daina M. Graybosch initiated coverage of I-Mab (IMAB) with an Outperform rating and $9 price target...

7d ago

IMAB

Trump Trade: Offshore wind seen with no future in the U.S. under Trump

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by...

29d ago

BEP

BTIG says buy I-Mab amid ‘misperceived’ China risk

BTIG analyst Justin Zelin notes that I-Mab (IMAB) shares have fallen about 20% following a New York Times...

30d ago

IMAB

I-Mab Reports H1 2025 Financial Results Amid Strategic Shift

The latest update is out from I-MAB ( ($IMAB) ). On October 6, 2025, I-Mab announced its financial...

4d ago

IMAB

I-Mab to Vote on Name Change to NovaBridge Biosciences

I-MAB ( ($IMAB) ) just unveiled an announcement. I-Mab has announced an Extraordinary General Meeting scheduled for October...

15d ago

IMAB

I-Mab initiated with a Buy at BTIG

BTIG initiated coverage of I-Mab (IMAB) with a Buy rating and $7 price target The firm believes givastomig...

1M ago

IMAB

I-Mab’s Strategic Expansion and Financial Stability Justify Buy Rating Amid Promising Clinical Developments

Needham analyst Gil Blum maintained a Buy rating on I-MAB today and set a price target of $6.00....

1M ago

IMAB

I-Mab announces accelerated investment in givastomig program

I-Mab (IMAB) announced accelerated investment in its lead program, givastomig, an investigational Claudin 18.2-directed bispecific antibody, including plans...

1M ago

IMAB

I-Mab Announces Leadership Changes and Accelerated Investment in Givastomig

An announcement from I-MAB ( ($IMAB) ) is now available. On September 3, 2025, I-Mab announced significant leadership...

1M ago

IMAB

I-Mab Strengthens Leadership with New Board Appointments and R&D Committee Formation

I-MAB ( ($IMAB) ) has provided an update. On August 22, 2025, I-Mab announced the appointment of Dr....

2M ago

IMAB

I-Mab appoints Lenz, Liu to board of directors, forms R&D Committee

I-Mab (IMAB) announced the appointment of independent directors, Dr. Robert Lenz and Ms. Xin Liu, to its Board...

2M ago

IMAB

I-Mab’s Q2 2025: Clinical Progress and Financial Strength

I-Mab Adr ( ($IMAB) ) has released its Q2 earnings. Here is a breakdown of the information I-Mab...

2M ago

IMAB

I-Mab price target raised to $6 from $5 at Needham

Needham raised the firm’s price target on I-Mab (IMAB) to $6 from $5 and keeps a Buy rating...

2M ago

IMAB

I-MAB’s Positive Outlook: Buy Rating Backed by Financial Stability and Promising Clinical Developments

Analyst Gil Blum of Needham maintained a Buy rating on I-MAB, boosting the price target to $6.00. Gil...

2M ago

IMAB

IMAB FAQ

What was I-MAB’s price range in the past 12 months?

I-MAB lowest stock price was $0.59 and its highest was $5.90 in the past 12 months.

What is I-MAB’s market cap?

I-MAB’s market cap is $346.07M.

When is I-MAB’s upcoming earnings report date?

I-MAB’s upcoming earnings report date is Nov 13, 2025 which is in 34 days.

How were I-MAB’s earnings last quarter?

I-MAB released its earnings results on Aug 20, 2025. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.054 by $0.024.

Is I-MAB overvalued?

According to Wall Street analysts I-MAB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does I-MAB pay dividends?

I-MAB does not currently pay dividends.

What is I-MAB’s EPS estimate?

I-MAB’s EPS estimate is -0.04.

How many shares outstanding does I-MAB have?

I-MAB has 81,660,350 shares outstanding.

What happened to I-MAB’s price movement after its last earnings report?

I-MAB reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.054. Following the earnings report the stock price went up 7.363%.

Which hedge fund is a major shareholder of I-MAB?

Currently, no hedge funds are holding shares in IMAB

I-MAB Stock Smart Score

Outperform

Fundamentals

Return on Equity

-22.44%

Trailing 12-Months

Asset Growth

-42.27%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

I-MAB

I-MAB (IMAB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The company is engaged in the development of innovative monoclonal antibodies and biologics, leveraging its integrated research and development capabilities. I-MAB aims to address unmet medical needs through its proprietary drug discovery and development platforms.

I-MAB (IMAB) Earnings & Revenues

Historic Earnings Reports

IMAB Stock 12 Month Forecast

Average Price Target

$7.40

▲(45.96% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","-1":"-$1","1.75":"$1.75","4.5":"$4.5","7.25":"$7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.86,4.2553846153846155,4.650769230769231,5.046153846153846,5.441538461538462,5.836923076923077,6.2323076923076925,6.627692307692309,7.023076923076923,7.418461538461539,7.813846153846154,8.20923076923077,8.604615384615386,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.86,4.132307692307692,4.404615384615385,4.676923076923077,4.94923076923077,5.2215384615384615,5.493846153846154,5.766153846153847,6.038461538461538,6.310769230769232,6.5830769230769235,6.855384615384615,7.127692307692309,{"y":7.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.86,4.024615384615385,4.189230769230769,4.3538461538461535,4.518461538461539,4.683076923076923,4.8476923076923075,5.012307692307692,5.176923076923077,5.341538461538462,5.506153846153846,5.670769230769231,5.835384615384616,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.81,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.34,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >